State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China.
Cancer Immunol Immunother. 2024 Feb 15;73(3):54. doi: 10.1007/s00262-023-03579-0.
Hypopharyngeal and laryngeal squamous cell carcinoma (SCC) account for 25-30% of head and neck SCC. Total laryngectomy, while effective, compromises the quality of life. Immune checkpoint inhibitors such as Camrelizumab offer potential in laryngeal preservation. The study investigated Camrelizumab combined with TP regimen as a neoadjuvant therapy for laryngeal preservation in advanced hypopharyngeal and laryngeal SCC.
A retrospective study was conducted at Sun Yat-sen University Cancer Center on patients diagnosed with locally advanced SCC of the hypopharynx and larynx from October 1, 2019, to October 25, 2022. The efficacy of a first-line treatment combining Camrelizumab (200 mg) and TP regimen (Albumin-bound paclitaxel at 260 mg/m and Cisplatin at 60 mg/m) was evaluated using RECIST 1.1 criteria. Outcomes included overall survival (OS), progression-free survival (PFS), laryngectomy-free survival (LFS), and response rates.
Of the 71 included patients, the median age was 60.7 years. Post the first-line treatment, 90.1% demonstrated an overall response. The one-year and two-year OS rates were 91.5% and 84.3%, respectively. One-year and two-year PFS rates were 92.9% and 83.9%, respectively, with LFS at 85.6% and 73.2%. The initial T4 stage as significantly associated with reduced OS and LFS. Skin reaction was the predominant adverse event.
The Camrelizumab-TP regimen demonstrated promising results for advanced hypopharyngeal/laryngeal SCC patients, exhibiting high response rates, OS, and LFS, positioning it as a potential primary option for laryngeal preservation. Further comprehensive, randomized controlled studies are imperative to validate these initial observations and elucidate the regimen's full clinical efficacy in optimizing laryngeal outcomes.
下咽和喉鳞状细胞癌（SCC）占头颈部 SCC 的 25-30%。全喉切除术虽然有效，但会影响生活质量。免疫检查点抑制剂，如卡瑞利珠单抗，为保留喉功能提供了可能。本研究探讨了卡瑞利珠单抗联合 TP 方案作为晚期下咽和喉鳞状细胞癌保留喉功能的新辅助治疗。
本研究是一项回顾性研究，纳入了 2019 年 10 月 1 日至 2022 年 10 月 25 日在中山大学肿瘤防治中心诊断为局部晚期下咽和喉 SCC 的患者。采用 RECIST 1.1 标准评估卡瑞利珠单抗（200mg）联合 TP 方案（白蛋白结合紫杉醇 260mg/m 和顺铂 60mg/m）一线治疗的疗效。主要终点是总生存期（OS）、无进展生存期（PFS）、喉无进展生存期（LFS）和缓解率。
本研究共纳入 71 例患者，中位年龄为 60.7 岁。一线治疗后，90.1%的患者达到了总体缓解。1 年和 2 年 OS 率分别为 91.5%和 84.3%，1 年和 2 年 PFS 率分别为 92.9%和 83.9%，LFS 率分别为 85.6%和 73.2%。初始 T4 期与 OS 和 LFS 降低显著相关。皮肤反应是最常见的不良反应。
卡瑞利珠单抗联合 TP 方案治疗晚期下咽/喉鳞状细胞癌患者显示出良好的疗效，具有较高的缓解率、OS 和 LFS，为保留喉功能提供了一种潜在的一线选择。需要进一步进行全面的、随机对照研究来验证这些初步观察结果，并阐明该方案在优化喉功能结局方面的全部临床疗效。
